CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership494,218 shares
Latest Disclosed Value $ 23,487,779
Dimensional Fund Advisors Lp reports 45.52% decrease in ownership of CRSP / CRISPR Therapeutics AG

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 494,218 shares of CRISPR Therapeutics AG (US:CRSP) valued at $23,509,950 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 907,107 shares of CRISPR Therapeutics AG. This represents a change in shares of -45.52% during the quarter. The current value of the position is $25,738,873 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 494,218 -412,889 -45.52 23,488 -50.63 0.0011
2026-02-12 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 907,107 30,078 3.43 47,573 -16.30 0.0100
2025-11-12 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 877,029 -40,683 -4.43 56,834 27.33 0.0122
2025-08-12 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 917,712 -19,433 -2.07 44,636 39.92 0.0103
2025-05-13 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 937,145 -10,156 -1.07 31,901 -14.44 0.0079
2025-02-13 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 947,301 122,695 14.88 37,283 -3.76 0.0090
2024-11-07 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 824,606 -125,543 -13.21 38,741 -24.52 0.0094
2024-08-09 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 950,149 19,094 2.05 51,326 -19.12 0.0134
2024-05-10 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 931,055 151,601 19.45 63,461 30.04 0.0172
2024-02-07 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 779,454 -100,347 -11.41 48,801 22.20 0.0142
2023-11-09 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 879,801 168,530 23.69 39,937 0.00 0.0131
2023-08-09 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 711,271 -48,464 -6.38 39,935 16.23 0.0127
2023-05-12 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 759,735 -15,076 -1.95 34,359 110,735.48 0.0116
2023-02-09 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 774,811 125,751 19.37 31 -99.93 0.0093
2022-11-10 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 649,060 209,134 47.54 42,414 58.63 0.0163
2022-08-12 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 439,926 199,939 83.31 26,738 77.46 0.0096
2022-05-13 2022-03-31 13F CRISPR THERAPEUTICS COM H17182108 239,987 -19,054 -7.36 15,067 -23.27 0.0046
2022-02-09 2021-12-31 13F CRISPR THERAPEUTICS COM H17182108 259,041 104,371 67.48 19,636 13.43 0.0059
2021-11-12 2021-09-30 13F CRISPR THERAPEUTICS COM H17182108 154,670 8,848 6.07 17,311 -26.60 0.0056
2021-08-12 2021-06-30 13F CRISPR THERAPEUTICS COM H17182108 145,822 7,072 5.10 23,584 39.58 0.0075
2021-05-14 2021-03-31 13F CRISPR THERAPEUTICS COM H17182108 138,750 31,103 28.89 16,897 2.43 0.0056
2021-03-08 2020-12-31 13F/A-2 CRISPR THERAPEUTICS COM H17182108 107,647 5,990 5.89 16,496 93.96 0.0060
2021-02-11 2020-12-31 13F CRISPR THERAPEUTICS COM H17182108 107,647 5,990 16,496 5,957.4784
2020-11-12 2020-09-30 13F CRISPR THERAPEUTICS COM H17182108 101,657 645 0.64 8,505 14.55 0.0036
2020-08-13 2020-06-30 13F CRISPR THERAPEUTICS COM H17182108 101,012 12,527 14.16 7,425 97.79 0.0033
2020-05-14 2020-03-31 13F CRISPR THERAPEUTICS COM H17182108 88,485 41,952 90.16 3,754 32.46 0.0020
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS COM H17182108 46,533 46,533 2,834 0.0010
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.